Tesla
TSLA
NVIDIA
NVDA
Palantir
PLTR
4
Apple
AAPL
5
Strategy
MSTR
US Stock MarketDetailed Quotes
CNTA Centessa Pharmaceuticals
- 15.800
- -0.430-2.65%
Close Mar 10 16:00 ET
- 15.360
- -0.440-2.78%
Pre 04:30 ET
1.80BMarket Cap-10.39P/E (TTM)
16.010High15.300Low1.21MVolume16.010Open16.230Pre Close19.01MTurnover1.67%Turnover RatioLossP/E (Static)113.85MShares19.09052wk High3.60P/B1.14BFloat Cap7.75052wk Low--Dividend TTM72.29MShs Float26.900Historical High--Div YieldTTM4.38%Amplitude2.885Historical Low15.728Avg Price1Lot Size
Centessa Pharmaceuticals Stock Forum
Dow Jones· 15 mins ago
Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares
BOSTON and LONDON, April 23, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for p...
⇨ held by 5 biopharma-focused hedge funds! 🔥
$Arcellx (ACLX.US)$ : Anito-cel (Ph 2)
$Adaptimmune Therapeutics (ADAP.US)$ : Afami-cel (PDUFA) ⏳
$Bicycle Therapeutics (BCYC.US)$ : BT8009 (Ph 1/2)
$Centessa Pharmaceuticals (CNTA.US)$ : LB101 (Ph 1/2)
$Day One Biopharmaceuticals (DAWN.US)$ : Tovorafenib (PDUFA) (check comments for details)
$Fate Therapeutics (FATE.US)$ : FT576 (Ph 1)
$Fusion Pharmaceuticals (FUSN.US)$ : FPI-2265 (Ph 2)
$GRCL: ...
Select biotech/pharma names showing strength following ESMO:
$Clovis Oncology (CLVS.US)$ +11.3%, $Cardiff Oncology (CRDF.US)$ +9%, $Immatics (IMTX.US)$ +8.3%, $IDEAYA Biosciences (IDYA.US)$ +8%, $Lyra Therapeutics (LYRA.US)$ +5.7%, $POINT Biopharma (PNT.US)$ +5.7%, $Edgewise Therapeutics (EWTX.US)$ +4.7%, $Concert Pharmaceuticals (CNCE.US)$ +3.6%, $Deciphera Pharmaceuticals (DCPH.US)$ +3.2%, $Veracyte (VCYT.US)$ +2.6%, $SpringWorks Therapeutics (SWTX.US)$ +2.3%, ...
• $American Express (AXP.US)$ : Baird Upgrades to Outperform from Neutral - PT $175
• $The AZEK (AZEK.US)$ : BofA Securities Upgrades to Buy from Neutral
• $Capital One Financial (COF.US)$ : Baird Upgrades to Outperform from Neutral - PT $145
• $Fifth Third Bancorp (FITB.US)$ : Baird Upgrades to Outperform from Neutral - PT $44
• $M&T Bank (MTB.US)$ : Baird Upgrades to Outperform from Neutral - PT $200 (from $175)
• $NextEra Energy Partners LP (NEP.US)$ : RBC Cap...
• $Repare Therapeutics (RPTX.US)$ +26.4% (announces worldwide license and collaboration agreement with Roche for camonsertib)
• $Chewy (CHWY.US)$+19.8% (Chewy stock soars on earnings. Here's what really mattered)
• $UiPath (PATH.US)$ +11.7% ( reported first-quarter revenue growth of 32% year-over-year to $245.1 million)
• $Pure Storage (PSTG.US)$ +10.6% (In reaction to earnings)
• $Credo Technology (CRDO.US)$ +10.2% (In reaction ...
The agreement will give Centessa subsidiary Orexia Therapeutics access to Schrodinger's computing platform. The platform allows for high performance computing in order to accurately predict the effectiveness of the target of interest.
The terms require Orexia to handle preclinical research activities, clinical development, and commercialization of potential candidates.
No comment yet